J&J MD&D segment sees 80 submissions in next two years

Johnson & Johnson's Medical Devices & Diagnostics segment has received more than a dozen regulatory approvals so far this year, and it plans to make approximately 80 significant submissions across its seven franchises between 2010 and 2012. In fact, the MD&D business segment, which generated $23.6 billion in sales in 2009 and became Johnson & Johnson's largest business segment, holds the No. 1 or 2 market positions in the majority of its markets. These facts were...

ReNeuron OK’d for world’s first stem cell trial for strokes

The UK's ReNeuron has been given a regulatory green light to launch the world's first human trial of a stem cell therapy for...

Neovasc completes first tranche of $1.329 million non-brokered private placement

--Proceeds will be Used to Fund Reducer(TM) COSIRA Multi-Center Clinical Trial-- VANCOUVER, Jan. 28 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC) today announced that it has completed the first tranche of a previously announced non-brokered private placement of approximately 7.4 million units at the price of $0.27per unit for aggregate gross proceeds of up to $2.0 million. The proceeds of the offering will be used primarily to fund the COSIRA trial - a multi-center clinical trial...

JDRF and BD Collaborate to Improve Insulin Pump Delivery

R&D Program Targets Opportunities to Improve Glucose Control and Help People with Diabetes Lead Healthier Lives NEW YORK and FRANKLIN LAKES, N.J., Jan. 19 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced...